Anti-vascular endothelial growth factor-A medications such as ranibizumab and bevacizumab were associated with significant short-term improvements and few adverse effects in patients with diabetic macular edema, an analysis in BMJ Open indicated. Researchers said anti-VEGFs may offer more consistent results compared with laser and steroid therapies.